Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q7Z3K3

UPID:
POGZ_HUMAN

ALTERNATIVE NAMES:
Suppressor of hairy wing homolog 5; Zinc finger protein 280E; Zinc finger protein 635

ALTERNATIVE UPACC:
Q7Z3K3; B4DTP8; B4DYL9; B7ZBY5; E9PM80; O75049; Q3LIC4; Q5SZS1; Q5SZS2; Q5SZS3; Q5SZS4; Q8TDZ7; Q9Y4X7

BACKGROUND:
Pogo transposable element with ZNF domain is integral to mitotic cell cycle, kinetochore assembly, and DNA repair. Its association with CBX5 and regulation of aurora kinase B underscores its importance in chromosome segregation and genomic integrity.

THERAPEUTIC SIGNIFICANCE:
Given its association with White-Sutton syndrome, exploring the functions of this protein offers a promising avenue for developing targeted therapies for this and potentially other genetic disorders. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.